{"id":196458,"date":"2026-11-02T05:45:11","date_gmt":"2026-11-02T05:45:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/196458\/"},"modified":"2026-11-02T05:45:11","modified_gmt":"2026-11-02T05:45:11","slug":"eli-lilly-tops-1-trillion-as-novo-nordisk-eats-the-losses-of-a-drug-war","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/196458\/","title":{"rendered":"Eli Lilly tops $1 trillion as Novo Nordisk eats the losses of a drug war"},"content":{"rendered":"<p>Eli Lilly&#8217;s obesity-drug growth has pushed its market value further above the trillion-dollar threshold while rival Novo Nordisk faces falling sales and intense pricing pressure.<\/p>\n<p>On October 29, Eli Lilly reported third-quarter revenue of $24.4 billion, up 39% from a year earlier. It also raised the midpoint of its full-year 2026 revenue guidance by $5.5 billion, to a new range of $91 billion to $92 billion. Shares closed 6.6% higher that day after touching $1,408.38, then reached a new intraday record of $1,449.68 on October 30. Lilly first crossed $1 trillion in market value in November 2025, becoming the first health-care company to reach that threshold; by October 30, 2026, its market capitalization was about $1.26 trillion. Mounjaro and Zepbound did most of the work. They are Lilly&#8217;s diabetes and obesity drugs, built on the same molecule, tirzepatide: Mounjaro sales rose 65% to $10.72 billion, Zepbound jumped 49% to $5.35 billion, and the two combined for more than $16 billion in a single quarter.<\/p>\n<p>CEO David Ricks said the quarter was driven by &#8220;broad global consumer demand for Mounjaro and Zepbound,&#8221; global launches of Lilly&#8217;s new oral pill Foundayo and wider U.S. insurance coverage for obesity treatment. Foundayo, known chemically as orforglipron, received FDA approval on April 1 under a priority voucher review completed 50 days after filing. Unlike the oral version of Wegovy, it can be taken at any time of day without food or water restrictions. Eligible commercially insured patients can pay as little as $25 a month, while self-pay prices start at $149 and vary by dose.<\/p>\n<p>Novo Nordisk isn&#8217;t losing this fight in real time this week. It lost a chunk of it back in February, when the company warned that 2026 sales and operating profit could fall between 5% and 13%. Shares fell sharply. The company shed close to $50 billion in market value after the warning. CEO Mike Doustdar called it a year of &#8220;unprecedented pricing pressure.&#8221; Chief Financial Officer Karsten Munk Knudsen said a bigger-than-expected shift of U.S. patients toward self-pay plans and rising insurer rebate demands were creating more pressure than the Trump administration&#8217;s Most Favored Nation policy. Novo also cited the expiration of semaglutide patents in some markets outside the United States.<\/p>\n<p>Novo reports its third-quarter results on November 4, and analysts expect lower earnings and revenue from a year earlier. A current consensus estimate puts earnings near $0.73 per ADR and revenue near $11.08 billion. Novo&#8217;s U.S.-listed shares were down about 20% over the twelve months through October 30, while Lilly&#8217;s were up about 68%. Two companies are selling into the same obesity boom and moving in opposite directions. The gap is now wide enough that you can measure it in market caps rather than percentage points.<\/p>\n<p>What&#8217;s happening underneath those numbers is a pricing fight Novo started losing despite having the earlier obesity drug. Wegovy launched years before Zepbound, but Lilly subsequently took the U.S. market-share lead. Lower-cost cash-pay channels and compounded GLP-1 products have intensified price competition, while Lilly launched Foundayo with self-pay prices starting at $149 a month.<\/p>\n<p>Novo is not finished, though. Wegovy sales have kept climbing even as the outlook darkened, and the company still has real scale, real manufacturing capacity and a deep pipeline. But a trillion-dollar valuation for one company, built substantially on taking volume from the other, is a hard thing to argue away. Frankly, the market has already rendered its verdict on which obesity-drug strategy it trusts going into 2027: the one that cut price and built an easier pill, not the one defending a franchise it built first.<\/p>\n<p>Novo&#8217;s report on November 4 is next. If the pricing damage shows up smaller than February&#8217;s guidance implied, that&#8217;s a real signal the worst is priced in. If it doesn&#8217;t, the gap between these two companies keeps widening.<\/p>\n<p>Also read: <a href=\"https:\/\/startupfortune.com\/thrive-holdings-agrees-to-buy-adt-for-153-billion-with-openai-backing\/\" rel=\"nofollow noopener\" target=\"_blank\">Thrive Holdings Agrees to Buy ADT for 15.3 Billion With OpenAI Backing<\/a> \u2022 <a href=\"https:\/\/startupfortune.com\/figma-opens-its-canvas-to-ai-coding-agents-answering-canvas-pivot\/\" rel=\"nofollow noopener\" target=\"_blank\">Figma Opens Its Canvas to AI Coding Agents, Answering Canva&#8217;s Pivot<\/a> \u2022 <a href=\"https:\/\/startupfortune.com\/justice-department-questions-nvidias-1293-billion-hugging-face-deal\/\" rel=\"nofollow noopener\" target=\"_blank\">Justice Department questions Nvidia&#8217;s $12.93 billion Hugging Face deal<\/a><\/p>\n<p><img class=\"sf-mpxc-logo\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/11\/metropolix-logo.webp\" alt=\"\" width=\"56\" height=\"51\" loading=\"lazy\" decoding=\"async\"\/><\/p>\n<p class=\"sf-mpxc-k\">The Metropolix, from Startup Fortune<\/p>\n<p class=\"sf-mpxc-act\"><a class=\"sf-mpxc-btn\" data-cta=\"\" href=\"https:\/\/metropolix.io\/?utm_source=startupfortune&amp;utm_medium=article-card&amp;utm_campaign=card\" rel=\"nofollow noopener\" target=\"_blank\"> \u2192<\/a><\/p>\n<p>This article is posted in <a href=\"https:\/\/startupfortune.com\/category\/business\/\" rel=\"nofollow noopener\" target=\"_blank\">Business News<\/a>, check it out for more related stories.<\/p>\n<p class=\"sf-community-signin-lead\">Almost there. Sign in and your reply posts straight away.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly&#8217;s obesity-drug growth has pushed its market value further above the trillion-dollar threshold while rival Novo Nordisk&hellip;\n","protected":false},"author":2,"featured_media":196459,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[3265,276,87876,87877,272,87878,87879,87880],"class_list":["post-196458","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-david-ricks","tag-eli-lilly","tag-eli-lilly-q3-2026-earnings","tag-eli-lilly-stock-hits-trillion-dollar-milestone","tag-novo-nordisk","tag-obesity-drug-market-share-2026","tag-weight-loss-drug-market-share-competition-dynamics","tag-zepbound-mounjaro-sales-growth"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117545266296659185","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/196458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=196458"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/196458\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/196459"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=196458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=196458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=196458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}